Literature DB >> 30100945

Bone and Calcified Soft Tissue Metastases of Medullary Thyroid Carcinoma Better Characterized on 18F-Fluoride PET/CT than on 68Ga-Dotatate PET/CT.

Paulo Schiavom Duarte1, Luciana Audi de Castroneves2, Heitor Naoki Sado1, Marcelo Tatit Sapienza1, Ana Amélia Fialho de Oliveira Hoff2, Carlos Alberto Buchpiguel1.   

Abstract

Herein, we report a case of a 19-year-old man with multiple endocrine neoplasia type 2B (MEN2B) and medullary thyroid carcinoma (MTC) diagnosed when he was 12 years of age. The patient had previously undergone total thyroidectomy, cervical radiotherapy, and chemotherapy. He progressed with known bone, pulmonary, and lymph node metastases and was scanned with 18F-fluoride (18F-NaF) and 68Ga-dotatate whole-body positron emission tomography/computed tomography (PET/CT) for metastatic disease monitoring. We found that the MTC bone metastases and soft tissue calcified metastases were better characterized on 18F-NaF PET/CT than on 68Ga-dotatate PET/CT. This case illustrates that the 18F-NaF PET/CT could be helpful not only to the detection of bone metastases but also to the detection of calcified soft tissue metastases in patients with MTC.

Entities:  

Keywords:  18F; 18F-NaF; 68Ga; Gallium-68; Medullary thyroid carcinoma; PET/CT

Year:  2018        PMID： 30100945      PMCID： PMC6066486          DOI： 10.1007/s13139-018-0527-8

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN： 1869-3474


  27 in total

Review 1.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

2.  The 2015 Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the "evidence-based" refusal to endorse them by EANM due to the "not evidence-based" marginalization of the role of Nuclear Medicine.

Authors:  Giorgio Treglia; Cumali Aktolun; Arturo Chiti; Savvas Frangos; Luca Giovanella; Martha Hoffmann; Ioannis Iakovou; Jasna Mihailovic; Bernd J Krause; Werner Langsteger; Frederik A Verburg; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-04-27       Impact factor: 9.236

Review 3.  Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone.

Authors:  N Ghanem; M Uhl; I Brink; O Schäfer; T Kelly; E Moser; M Langer
Journal:  Eur J Radiol       Date:  2005-07       Impact factor: 3.528

4.  Kinetic analysis of 18F-fluoride PET images of breast cancer bone metastases.

Authors:  Robert K Doot; Mark Muzi; Lanell M Peterson; Erin K Schubert; Julie R Gralow; Jennifer M Specht; David A Mankoff
Journal:  J Nucl Med       Date:  2010-03-17       Impact factor: 10.057

5.  Biomarker-based risk stratification for previously untreated medullary thyroid cancer.

Authors:  Andreas Machens; Henning Dralle
Journal:  J Clin Endocrinol Metab       Date:  2010-03-25       Impact factor: 5.958

6.  Usefulness of the 99mTc-MDP scan in the detection of calcified liver metastases.

Authors:  K Tokuue; M Furuse
Journal:  Nuklearmedizin       Date:  1990-11       Impact factor: 1.379

7.  Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid.

Authors:  M Papotti; U Kumar; M Volante; C Pecchioni; Y C Patel
Journal:  Clin Endocrinol (Oxf)       Date:  2001-05       Impact factor: 3.478

8.  Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging.

Authors:  Clarisse Dromain; Thierry de Baere; Jean Lumbroso; Hubert Caillet; Agnès Laplanche; Valerie Boige; Michel Ducreux; Pierre Duvillard; Dominique Elias; Martin Schlumberger; Robert Sigal; Eric Baudin
Journal:  J Clin Oncol       Date:  2005-01-01       Impact factor: 44.544

9.  Pathological and clinical findings in a series of 67 cases of medullary carcinoma of the thyroid.

Authors:  E D Williams; C L Brown; I Doniach
Journal:  J Clin Pathol       Date:  1966-03       Impact factor: 3.411

Review 10.  Peptide Receptor Radionuclide Therapy (PRRT) of Medullary and Nonmedullary Thyroid Cancer Using Radiolabeled Somatostatin Analogues.

Authors:  Ali Salavati; Ameya Puranik; Harshad R Kulkarni; Hendra Budiawan; Richard P Baum
Journal:  Semin Nucl Med       Date:  2016-05       Impact factor: 4.446
View more
  2 in total

1.  Letter to the Editor: 18F-NaF not cited in the EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma.

Authors:  Paulo Schiavom Duarte
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-11-18       Impact factor: 9.236

2.  Comparison of 18F-NaF PET/CT with Other Imaging Methods in the Detection of Bone Metastases in Patients with Medullary Thyroid Cancer: a Report of a Series of 31 Cases.

Authors:  Cristina Emiko Ueda; Paulo Schiavom Duarte; Luciana Audi de Castroneves; George Barbério Coura-Filho; Heitor Naoki Sado; Marcelo Tatit Sapienza; Ana Oliveira Hoff; Carlos Alberto Buchpiguel
Journal:  Nucl Med Mol Imaging       Date:  2020-09-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.